Boston Scientific推出紫杉醇洗脱冠状动脉支架

一种紫杉醇洗脱的冠状动脉支架系统整合了下一代支架技术，具有高度灵活的细胞几何学、超薄支柱以及均匀一致的细胞分布。

这种支架叫做Taxus Liberte，是波士顿科学公司的产品，拥有Veriflex设计的特性。这种新型平台为战胜解剖学难题提供了更好的输送放置特性和一致性。它还同时具有增强TrakTip导管尖端放置在输送导管上，这样提供了更好的穿越病变区域的功能。除此之外，TrakTip需要穿越的病变区域较小，这也增强了穿越功能。Taxus Liberte现在已经在全球18个国家上市。

Mercy医院和Auckland城市医院介入心血管医师John Ormiston医生评论说：“我个人使用Liberte系统的经验证实该产品是支架工艺所取得的一个巨大进步。它适应血管壁的能力是无与伦比的，而且它易于输送放置的特性使得医生更加容易的到达一些很难触及的病变区域。”

为了得到美国食品药品管理局对这种支架系统的批准，波士顿科学公司已经宣布开始临床试验。公司第一代药物洗脱支架系统，Taxus Express2紫杉醇洗脱冠状动脉支架系统，是世界上冠状动脉支架市场首屈一指的产品。
 
Paclitaxel-Eluting Coronary Stent
 
A paclitaxel-eluting coronary stent system incorporates a next-generation stent with highly flexible cell geometry, thin struts, and uniform cell distribution.

Called Taxus Liberte, the stent is the product of Boston Scientific corp. (Natick, MA, USA) and features the Veriflex design. This new platform offers better delivery and conformity in challenging anatomy. It also features the enhanced TrakTip catheter tip, mounted on the delivery catheter, which provides better lesion crossability. In addition, TrakTip has a low lesion-entry profile, which further improves crossability. The Taxus Liberte is now being marketed in 18 countries around the world.

“My experience with the Liberte system demonstrates that it represents a dramatic step forward in stent technology,” commented John Ormiston, M.D., interventional cardiologist at Mercy Hospital and Auckland City Hospital (New Zealand). “Its ability to conform to the vessel wall is outstanding, and its ease of deliverability allows us to more easily reach some of the difficult lesions.”

Boston Scientific has announced enrollment in a clinical trial designed to support approval of the stent system by the U.S. Food and Drug Administration (FDA). The company’s first-generation drug-eluting stent system, the Taxus Express2 paclitaxel-eluting coronary stent system, is the leader of the worldwide coronary stent market.